Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant PK/PD in Pediatric PONV
NCT01732458Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2013
- Primary completion
- Sep 2016
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of aprepitant in postoperative nausea and vomiting (PONV) (4 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-time Curve of Aprepitant From Time 0 to the Last Measurable Concentration, Maximum Concentration of Aprepitant and 6 more. Started Feb 2013; status: completed.
02
Drugs
aprepitant
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on NCT01732458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01732458.